Evidence map›Paper›PMID 38235079›Full record

ArticleNanoscale advances2024

Tuning of TRAIL clustering on the surface of nanoscale liposomes by phase separation.

Zhenjiang Zhang, Michael R King

Open access · goldAbstract read
In one paragraph

Article in Nanoscale advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zhenjiang ZhangDepartment of Biomedical Engineering, Vanderbilt University 2414 Highland Ave Nashville TN 37212 USA mike.king@vanderbilt.edu.
Michael R KingDepartment of Biomedical Engineering, Vanderbilt University 2414 Highland Ave Nashville TN 37212 USA mike.king@vanderbilt.edu.ORCID https://orcid.org/0000-0002-0223-7808
Vanderbilt University · US

Funding

Super Natural Killer Cells That Target Metastases in the Tumor-Draining Lymph NodesR01CA203991 · NCI · VANDERBILT UNIVERSITY · PI KING, MICHAEL R. · 2017 to 2021
$1.9M
Enabling Technology to Study Mechanosensitive and Mechanoresistant Cancer Cells in FlowR01CA256054 · NCI · VANDERBILT UNIVERSITY · PI KING, MICHAEL R. · 2021 to 2025
$1.8M
NCI NIH HHS R01 CA203991NCI NIH HHS R01 CA256054
6 · The paper itself

Abstract

Phase-separated liposomes were used to formulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a protein that selectively kills cancer cells while sparing most healthy ones. By controlling the average number of TRAIL molecules per liposome, we demonstrate the ability to tune the formation of TRAIL clusters and their resulting apoptotic activity.

Identifiers

PMID38235079
PMCPMC10790813
OpenAlexW4390429653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.